Dexcom has revealed a new wearable metabolic monitor designed for individuals with Type 2 diabetes who do not use insulin. The device, which is expected to launch in about a year, aims to reduce healthcare costs by providing daily decision support and helping patients manage their condition through tracking exercise, food, and medications. Dexcom’s CEO, Kevin Sayer, highlighted the device’s potential to assist millions of non-insulin-dependent Type 2 diabetes patients and educate prediabetic individuals on the impact of their daily habits. Additionally, Dexcom’s G7 CGM received market approval from Health Canada, offering real-time and predictive alerts for insulin-dependent diabetes management.
Dexcom has unveiled a novel metabolic monitor aimed at reducing healthcare costs for individuals with Type 2 diabetes who do not require insulin treatment. CEO Kevin Sayer emphasized the need to change existing trends in diabetes management.
As a leading manufacturer of continuous glucose monitors, Dexcom is developing a specialized monitor for Type 2 diabetes patients who do not rely on insulin. The device features a 15-day sensor and offers a cash-pay option for patients without Medicare coverage or health insurance, providing daily decision support.
Given that over 37 million Americans are affected by diabetes, healthcare technology developers and researchers are striving to enhance prevention, early detection, management, and care for this condition, according to the U.S. Centers for Disease Control.
Dexcom CEO Kevin Sayer highlighted the three critical decisions faced by individuals with Type 2 diabetes who do not use insulin—exercise, food, and medication. He explained that the company’s upcoming sensor, slated for launch in approximately a year, will assist millions of non-insulin-dependent Type 2 diabetes patients and enable prediabetic patients to understand how their daily habits impact their condition. Sayer shared this information during a recent American Diabetes Conference in San Diego, as reported by the San Diego Union-Tribune.
While 10% of adults worldwide are diagnosed with Type 2 diabetes mellitus, only a fraction require multiple medications to manage their blood glucose levels and prevent complications, as indicated by researchers at the University of Utah Health, Regenstrief Institute, and Hitachi. These researchers are exploring the use of artificial intelligence to analyze electronic health record data for Type 2 diabetes characteristics.
Sayer explained that Dexcom’s forthcoming wearable medical device, currently under review by the U.S. government, will allow patients to track meal planning, exercise, and medications—both for diabetes and other conditions.
Sayer emphasized the importance of wearable glucose monitors demonstrating their ability to reduce healthcare costs across the system, stating that a quarter of healthcare spending in the United States is allocated to diabetes.
To further expand its offerings, Dexcom announced that its G7 CGM has obtained market approval from Health Canada. This device, approved in the U.S. in December, features predictive urgent low-alert functionality in addition to real-time alerts for individuals using insulin to manage their diabetes. Sayer noted in January that Dexcom CGMs have become more interoperable and secure with the introduction of the G7 platform, as he spoke with MobiHealthNews.
